[Federal Register: May 17, 1999 (Volume 64, Number 94)]
[Rules and Regulations]
[Page 26670]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr17my99-5]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 522
Implantation or Injectable Dosage Form New Animal Drugs;
Oxytetracycline Injection
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval of a supplemental abbreviated new
animal drug application (ANADA) filed by Boehringer Ingelheim
Vetmedica, Inc. The supplemental ANADA provides for establishment of a
28-day withdrawal period for subcutaneous use of oxytetracycline
injection in cattle and for intramuscular use in swine.
EFFECTIVE DATE: May 17, 1999.
FOR FURTHER INFORMATION CONTACT: William T. Flynn, Center for
Veterinary Medicine (HFV-133), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855, 301-827-7570.
SUPPLEMENTARY INFORMATION: Boehringer Ingelheim Vetmedica, Inc., 2621
North Belt Highway, St. Joseph, MO 64506, filed supplemental ANADA 200-
008 that provides for establishment of a 28-day withdrawal period for
subcutaneous use in cattle and intramuscular use in swine of
OxytetTM 200 and Bio-Mycin 200 (oxytetracycline
injection). The 28-day withdrawal period for the intravenous and
intramuscular use of oxytetracycline injection in cattle, assigned as
part of the original approval, remains unchanged. The drug is for
intramuscular, subcutaneous, or intravenous treatment of beef cattle
and nonlactating dairy cattle as follows: (1) Bacterial pneumonia and
shipping fever complex associated with Pasteurella spp. and Haemophilus
spp.; (2) infectious bovine keratoconjunctivitis (pinkeye) caused by
Moraxella bovis; (3) foot rot and diptheria caused by Fusobacterium
necrophorum; (4) bacterial enteritis (scours) caused by Escherichia
coli; (5) wooden tongue caused by Actinobacillus lignieresii; (6)
leptospirosis caused by Leptospira pomona; and (7) wound infections and
acute metritis caused by strains of streptococcal and staphylococcal
organisms. The drug is for intramuscular use in swine for treatment of
bacterial enteritis (scours, colibacillosis) caused by E. coli,
pneumonia caused by P. multocida, and leptospirosis caused by L.
pomona, and in sows as an aid in the control of infectious enteritis
(baby pig scours, colibacillosis) in suckling pigs caused by E. coli.
The ANADA is approved as of March 16, 1999, and the regulations are
amended by revising Sec. 522.1660(d)(2)(iii) (21 CFR
522.1660(d)(2)(iii)) to reflect the approval. Because the current
regulation failed to reflect the previously established 36-day
withdrawal period for subcutaneous use of oxytetracycline injection in
cattle, no revision to Sec. 522.1660(d)(1)(iii) is required for this
supplemental approval that establishes a 28-day withdrawal period for
subcutaneous use of oxytetracycline injection in cattle. The basis of
approval is discussed in the freedom of information summary.
In accordance with the freedom of information provisions of 21 CFR
part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness
data and information submitted to support approval of this application
may be seen in the Dockets Management Branch (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852,
between 9 a.m. and 4 p.m., Monday through Friday.
The agency has determined under 21 CFR 25.33(a)(1) that this action
is of a type that does not individually or cumulatively have a
significant effect on the human environment. Therefore, neither an
environmental assessment nor an environmental impact statement is
required.
List of Subjects in 21 CFR Part 522
Animal drugs.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is
amended as follows:
PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
1. The authority citation for 21 CFR part 522 continues to read as
follows:
Authority: 21 U.S.C. 360b.
2. Section 522.1660 is amended by revising paragraph (d)(2)(iii) to
read as follows:
Sec. 522.1660 Oxytetracycline injection.
* * * * *
(d) * * *
(2) * * *
(iii) Limitations. Administer intramuscularly. Do not inject more
than 5 milliliters per site in adult swine. Discontinue treatment at
least 28 days prior to slaughter when provided by 000010, 000069,
011722, 053389, 059130, and 061623.
Dated: May 3, 1999.
Margaret Ann Miller,
Acting Director, Office of New Animal Drug Evaluation, Center for
Veterinary Medicine.
[FR Doc. 99-12284 Filed 5-14-99; 8:45 am]
BILLING CODE 4160-01-F